$268 Million is the total value of SR ONE CAPITAL MANAGEMENT, LP's 6 reported holdings in Q1 2023. The portfolio turnover from Q4 2022 to Q1 2023 was 20.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| ARCELLX INC. | $169,455,216 | -0.5% | 5,500,007 | 0.0% | 63.12% | +1.5% | ||
| DSGN | DESIGN THERAPEUTICS INC | $37,657,767 | -43.8% | 6,526,476 | 0.0% | 14.03% | -42.6% | |
| New | MINERALYS THERAPEUTICS | $28,103,436 | – | 1,794,600 | +100.0% | 10.47% | – | |
| SBTX | Buy | ARS PHARMACEUTICALS | $26,123,999 | +1.8% | 4,012,903 | +33.3% | 9.73% | +3.8% |
| NKTX | NKARTA INC. | $4,733,332 | -40.7% | 1,333,333 | 0.0% | 1.76% | -39.5% | |
| EFFECTOR THERAPEUTICS INC | $2,387,740 | -18.6% | 6,822,114 | 0.0% | 0.89% | -17.0% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR/A filed 2023-05-19
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| DESIGN THERAPEUTICS INC | 8 | Q3 2023 | 68.1% |
| EFFECTOR THERAPEUTICS INC | 8 | Q3 2023 | 31.9% |
| ARCELLX INC. | 7 | Q3 2023 | 72.6% |
| NKARTA INC. | 6 | Q3 2023 | 8.0% |
| ARS PHARMACEUTICALS INC | 4 | Q3 2023 | 11.6% |
| MINERALYS THERAPEUTICS INC | 3 | Q3 2023 | 13.2% |
View SR ONE CAPITAL MANAGEMENT, LP's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-12 |
| 13F-HR | 2023-11-13 |
| 13F-HR | 2023-08-10 |
| 13F-HR/A | 2023-05-19 |
| 13F-HR | 2023-05-09 |
| 13F-HR | 2023-02-08 |
| 13F-HR | 2022-11-08 |
| 13F-HR | 2022-08-02 |
| 13F-HR | 2022-05-10 |
| 13F-HR | 2022-02-14 |
View SR ONE CAPITAL MANAGEMENT, LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.